Comparison of topical dexamethasone and topical FK506 treatment for the experimental allergic conjunctivitis model in Balb/c mice

Japanese Journal of Ophthalmology

Volumn 49, Issue 3, 2005, Pages 205-210

  Shoji, Jun ^a   Sakimoto, Tohru ^a   Muromoto, Keiko ^a   Inada, Noriko ^a   Sawa, Mitsuru ^a   Ra, Chisei ^b  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

Allergic conjunctivitis; Balb c mice; C gene; Dexamethasone; Eosinophil; FK506

Indexed keywords

ALKALINE PHOSPHATASE; ALUMINUM HYDROXIDE; CD4 ANTIGEN; DEXAMETHASONE; EYE OINTMENT; OVALBUMIN; SANTEZONE; TACROLIMUS; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL INFILTRATION; CONJUNCTIVA; CONTROLLED STUDY; DRUG EFFICACY; EOSINOPHIL; EXPERIMENTAL MODEL; EYE; EYELID; FROZEN SECTION; GENE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LACRIMAL GLAND; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PRODUCTIVE C EPSILON GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIZATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CONJUNCTIVITIS, ALLERGIC; DEXAMETHASONE; DISEASE MODELS, ANIMAL; EOSINOPHILS; GENE EXPRESSION; GLUCOCORTICOIDS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; MALE; MICE; MICE, INBRED BALB C; OVALBUMIN; RECEPTORS, ANTIGEN, T-CELL; TACROLIMUS;

EID: 21144439883     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10384-004-0187-3     Document Type: Article

References (20)

1. Tuft SL, Cree IA, Woods M, Yorston D. Limbal vernal keratoconjunctivitis in the tropics. Ophthalmology 1998;105:1489-1493.
2. BenEzra D, Pe'er J, Brodsky M, Cohen E. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol 1986;101:278-282.
3. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990;110:641-645.
4. Bleik JH, Khafid F, Tabbara F. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991;98:1679-1684.
5. Andersson J, Nagy S, Groth CG, Andersson U. Effects of FK506 and cyclosporine A on cytokine production studied in vitro at a single-cell level. Immunology 1992;75:136-142.
6. Wang SC, Morel PA, Wang Q, Jordan ML, Simmons RL, Tweardy DJ. A dual mechanism of immunosuppression by FK-506. Transplantation 1993;56:978-985.
7. de Paulis A, Crillo R, Ciccarelli A, de Crescenzo G, Oriente A, Marone G. Characterization of the anti-inflammatory effect of FK-506 on human mast cells. J Immunol 1991;147:4278-4285.
8. Iwamoto H, Yoshida H, Yoshida O, Fukushima A, Ueno H. Inhibitory effects of FK506 on the development of experimental allergic/immune-mediated blephaloconjunctivitis in Lewis rats by systemic but not by topical administration. Graefes Arch Clin Exp Ophthalmol 1999;237:407-414.
9. Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003;135:297-302.
10. Nagai H, Hiyama H, Matsuo A, Ueda Y, Inagaki N, Kawada K. FK-506 and cyclosporine A potentiate the IgE antibody production by contact sensitization with hapten in mice. J Pharmacol Exp Ther 1997;283:321-327.
11. Magone MT, Chan CC, Rizzo LV, Kozhich AT, Whitcup SM. A novel murine model of allergic conjunctivitis. Clin Immunol Immunopathol 1998;87:75-84.
12. Merayo-Lloves J, Zhao TZ, Dutt JE, Foster CS. A new murine model of allergic conjunctivitis and effectiveness of nedocromil sodium. J Allergy Clin Immunol 1996;97:1129-1140.
13. Sengoku T, Sakuma S, Satoh S, et al. Effect of FK506 eye drops on late and delayed-type responses in ocular allergy models. Clin Exp Allergy 2003;33:1555-1560.
14. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337:816-821.
15. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001;44:S28-S38.
16. Durham SR, Gould HJ, Thienes CP, et al. Expression of ε germ-line gene transcripts and mRNA for the ε heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. Eur J Immunol 1997;27:2899-2906.
17. Hiratsuka S, Yoshida A, Ishioka C, Kimata H. Enhancement of in vitro spontaneous IgE production by topical steroids in patients with atopic dermatitis. J Allergy Clin Immunol 1996;98:107-113.
18. Benson M, Strannegard IL, Strannegard O, Wennergren G. Topical steroid treatment of allergic rhinitis decreases nasal fluid TH2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN-γ, IL-1β, or neutrophils. J Allergy Clin Immunol 2000;106:307-312.
19. Kawamura N, Furuta H, Tame A, et al. Extremely high serum level of IgE during immunosuppressive therapy: paradoxical effect of cyclosporine A and tacrolimus. Int Arch Allergy Immunol 1997;112:422-424.
20. Kimata H. Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Ann Allergy Asthma Immunol 1999;82:293-295.